Buspirone: multicenter efficacy study.
The efficacy and safety of buspirone (Buspar), diazepam (Valium), and placebo were compared in a 3-week double-blind study of 131 patients with scores of at least 15 on the Hamilton Rating Scale for Anxiety. Active drugs were administered orally in 5-mg tablets to a maximum dose of 10 mg t.i.d. Buspirone was given to 43 patients, diazepam to 46 and placebo to 42. There was significant improvement in all three treatment groups at 1 and 2 weeks, with further significant improvement with both active drugs, but not with placebo, at 3 weeks. The incidence of side effects reported voluntarily by patients was similar with the two active drugs, but drowsiness was significantly more frequent with diazepam.
D000328:Adult; D000368:Aged; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000523:psychology; D002065:Buspirone; D002986:Clinical Trials as Topic; D003975:Diazepam / Q000009:adverse effects / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D012894:Sleep Stages
D014151:Anti-Anxiety Agents; D010919:Placebos; D011743:Pyrimidines; D003975:Diazepam; D002065:Buspirone